Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status

International Journal of Cancer

Volumn 126, Issue 6, 2010, Pages 1445-1453

  Murphy, Niamh C ^a   Biankin, Andrew V ^a,b,c   Millar, Ewan K A ^a,b,d,e   McNeil, Catriona M ^a,f,g   O'Toole, Sandra A ^a,g,h   Segara, Davendra ^a,i   Crea, Paul ⁱ   Olayioye, Monilola A ^j,n   Lee, C Soon ^e,k   Fox, Stephen B ^k   Morey, Adrienne L ^l   Christie, Michael ^m   Musgrove, Elizabeth A ^a,b   Daly, Roger J ^a,b   Lindeman, Geoffrey J ^j,m   Henshall, Susan M ^a,b   Visvader, Jane E ^j   Sutherland, Robert L ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ ST VINCENT'S CLINIC   (Australia)

^j WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^k UNIVERSITY OF MELBOURNE   (Australia)

^l ST VINCENT S HOSPITAL   (Australia)

^m ROYAL MELBOURNE HOSPITAL   (Australia)

ⁿ UNIVERSITY OF STUTTGART   (Germany)

more..

Author keywords

Breast cancer; HER2 Neu; STARD10; Triple negative breast cancer

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; PHOSPHOLIPID TRANSFER PROTEIN; PROTEIN STARD10; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME; UNIVARIATE ANALYSIS;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PHOSPHOPROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 74949132454     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24826     Document Type: Article

References (30)

1. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, Peterse JL, Mukai K, Tabar L, Jacquemier J, Cornelisse CJ, Sasco AJ, et al. Invasive breast carcinomas. In: Tavassoli FA, Devilee P, eds. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Lyon: IARC Press, 2003. 13.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
4. Early Breast Cancer Trialists' Collaborative Group.Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
5. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC, Jr.American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
6. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153.
7. Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN.HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-11.
8. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR, De Placido S.c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996;14:2702-8.
9. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW.Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999;79:1220-6.
10. Cleator S, Heller W, Coombes RC.Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44.
11. Rakha EA, Reis-Filho JS, Ellis IO.Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
12. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
13. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, et al. A multigene assay to predict recurrence of tamoxifen treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
15. Olayioye MA, Hoffmann P, Pomorski T, Armes J, Simpson RJ, Kemp BE, Lindeman GJ, Visvader JE.The phosphoprotein STARD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation. Cancer Res 2004; 64:3538-44.
16. Alpy F, Tomasetto C.Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J Cell Sci 2005;118: 2791-801.
17. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43.
18. Tavassoli F, Devilee P, eds. WHO classification of tumours: pathology and genetics tumours of the breast and female genital organs. Lyon: IARC Press,2003.
19. Elston CW, Ellis IO.Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19: 403-10.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
21. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ.Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7: 389-97.
22. Olayioye MA, Vehring S, Muller P, Herrmann A, Schiller J, Thiele C, Lindeman GJ, Visvader JE, Pomorski T.STARD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein. J Biol Chem 2005;280:27436-42.
23. Yamanaka M, Koga M, Tanaka H, Nakamura Y, Ohta H, Yomogida K, Tsuchida J, Iguchi N, Nojima H, Nozaki M, Matsumiya K, Okuyama A, et al. Molecular cloning and characterization of phosphatidylcholine transfer protein-like protein gene expressed in murine haploid germ cells. Biol Reprod 2000;62:1694-701.
24. Seldin DS, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I.CK2 as a positive regulator of Wnt signaling and tumourigenesis. Mol Cell Biochem 2005; 274:63-7.
25. Landesman-Bollag E, Lle Romieu-Mourez RE, Song DH, Sonenshein GE, Cardiff RD, Seldin DS.Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20: 3247-57.
26. Olayioye MA, Buchholz M, Schmid S, Schoffler P, Hoffmann P, Pomorski T.Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity. J Biol Chem 2007;282: 22492-8.
27. Musgrove E, Sergio CM, Loi S, Inman CK, Anderson LR, Alles MC, Pinese M, Caldon CE, Schutte J, Gardiner-Garden M, Ormandy CJ, McArthur G, et al. Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer. PLoS One 2008;3: e2987.
28. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9:R37.
29. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL.Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006;98:1420-4.
30. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B.The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 2002; 99:11890-5.